Microbiotix, Inc.

SEOUL, South Korea and KUMASI, Ghana, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The West Africa Centre for Innovative Research and Care (WAFCIRC) welcomed MicrobiotiX in Ghana for a formal signing ceremony, marking a historic memorandum of understanding (MoU) and the launch of a strategic research collaboration for the clinical advancement of bacteriophage-based therapies to combat antimicrobial resistance (AMR) across Africa. The signing ceremony was attended by Dr. Dongeun Yong, Chief Executive Officer of MicrobiotiX, and Dr. John Adabie, Director of WAFCIRC, underscoring a shared commitment to addressing one of the region’s most urgent public health challenges. AMR places a disproportionate burden on sub-Saharan Africa, where constrained access to effective antibiotics has amplified the impact of AMR-associated infections. Through this agreement, MicrobiotiX aims to expand its clinical research footprint beyond Asia into regions with significant unmet medical need. With a clinical program already underway in South Korea, the collaboration represents a strategic step toward globalizing MicrobiotiX’s development efforts and generating clinical evidence across diverse patient populations. Under the MoU and the accompanying research collaboration agreement, MicrobiotiX and the WAFCIRC will conduct clinical studies to analyze AMR-associated patient samples across a range of infectious diseases and to assess the potential efficacy of bacteriophage-based therapeutic candidates. WAFCIRC, in partnership with four clinical sites in Ghana, will lead study execution, including clinical operations, patient engagement, and data management. MicrobiotiX will provide bacteriophage therapeutic candidates manufactured at its in-house GMP facility, along with funding and technical documentation to support study implementation. “Our goal is not only to develop new therapeutics, but to establish a scalable model for clinically advancing phage therapies in partnership with local institutions. We are committed to supporting high-quality studies and knowledge transfer that strengthen long-term regional capability centered around AMR”, said Dr. Dongeun Yong, CEO of MicrobiotiX. “AMR is a daily clinical reality in our region. This partnership brings a high-potential modality into a locally led clinical research framework—so that innovation is evaluated against real patient needs and real health-system constraints”, said Dr. John Adabie, Director of WAFCIRC. Beyond product development, the partnership also aims to strengthen regional research capacity and contribute to broader global efforts to improve preparedness for, and response to, drug-resistant infections. By embedding phage research within African healthcare institutions and translating findings into actionable clinical evidence, the collaboration seeks to ensure emerging therapeutic approaches reflect the needs and on-the-ground realities of low- and middle-income countries while establishing a scalable model for expansion across Africa. By linking locally led clinical research with therapeutics development and manufacturing capabilities, WAFCIRC and MicrobiotiX aim to accelerate evaluation of phage-based options that could complement antimicrobial stewardship efforts and expand the clinical toolkit as resistance continues to rise. About MicrobiotiX MicrobiotiX is a clinical-stage biotechnology company focused on the development of bacteriophage-based therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, with an initial focus on respiratory diseases. The Company is advancing a pipeline of phage cocktail candidates targeting high-priority pathogens including Pseudomonas aeruginosa and Klebsiella pneumoniae, which are responsible for acute and chronic respiratory tract infections. MicrobiotiX leverages a proprietary bacteriophage library and integrated drug development capabilities, including PK/PD modeling and antibiotic synergy analysis, to support clinical translation. The Company operates a GMP-grade phage manufacturing facility to enable in-house production of drug material and support ongoing and future clinical development. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1a2b9d0-1e9e-4b18-9388-c8a8db9d6c28 bd@microbiotix.net

SEOUL, South Korea, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MicrobiotiX, a company specializing in the development of novel bacteriophage therapeutics, announced on the 12th of November 2025 that it has signed a memorandum of understanding (MoU) with the West Africa Centre for Innovative Research and Care (WAFCIRC), working with Komfo Anokye Teaching Hospital (KATH) and other tertiary hospitals in Ghana, to collaborate on the clinical research of bacteriophage-based therapies. The collaboration aims to lay the groundwork for the clinical validation of therapeutics targeting antimicrobial resistance (AMR) and multidrug-resistant (MDR) bacteria, while expanding treatment options for patients in African regions where access to antibiotics is limited. Under the MoU, the two institutions will conduct studies that analyze AMR and MDR related clinical samples from patients with a range of infections and evaluate the efficacy of bacteriophage therapeutics designed to address these challenges. WAFCIRC, in partnership with KATH, recognized as one of Ghana’s leading hospitals with strong critical care capabilities, will oversee the execution of the research, including clinical operations and data management. MicrobiotiX will provide its bacteriophage therapeutic candidates manufactured at its own Good Manufacturing Practice (GMP) facility and will support the collaboration through the provision of research funding and technical documentation. By combining the strengths of both organizations, the partnership is expected to serve as an important milestone in strengthening infectious disease preparedness and response in regions that are particularly vulnerable to antimicrobial resistance. Starting in Ghana, MicrobiotiX plans to expand the scope of collaboration across Africa, with the goal of providing more patients with innovative alternative treatment options. A MicrobiotiX representative stated, “This collaboration is a meaningful first step toward addressing the growing challenge of antimicrobial resistance on the African continent. It will help alleviate unmet medical needs in low- and middle-income countries while contributing to global efforts to tackle AMR·MDR.” MicrobiotiX is currently developing a bacteriophage therapeutic targeting patients with acute Pseudomonas aeruginosa pneumonia as its lead pipeline candidate. The candidate received approval for a Phase 1 human clinical trial (IND) from the Korean Ministry of Food and Drug Safety on October 21, 2025. bd@microbiotix.net

Sept. 03, 2025 -- MicrobiotiX, a biotech developing novel bacteriophage-based therapeutics, announced on the 29th that it has completed an extended Series B investment round totaling 20 billion KRW. MicrobiotiX’s cumulative investment amount across rounds has now reached 29 billion KRW. Following a 15 billion KRW Series B investment secured in October of 2024, MicrobiotiX completed the final closing of the round this month by securing an additional 5 billion KRW from new investors, including Paratus Investment, Pureun Investment, and OTIUM CAPITAL. MicrobiotiX is a bacteriophage therapy company targeting diseases caused by super bacteria (multidrug-resistant bacteria). The company possesses a platform for phage therapy development, which includes a phage library panel targeting multidrug-resistant bacteria, an in silico module, and a cGMP-grade phage manufacturing facility. MicrobiotiX was recently selected for the Korean Ministry of Health and Welfare’s “Infectious Disease Prevention and Treatment Technology Development Project” seeking clinical stage assets targeting unmet needs. The clinical award is worth 2.5 billion KRW. With this support, MicrobiotiX plans to begin the first-ever human clinical trial of phage therapy in Korea. The company has now secured critical government funding that will accelerate research and development for the commercialization of phage therapies and subsequent pipeline expansion. Dongeun Yong, the CEO of MicrobiotiX, said in a statement that, “With this investment and the government project selection, MicrobiotiX seeks to establish itself and Korea as a global leader in the phage therapy field. Through conducting the first clinical trial of its kind in Korea, we are responding to the global health crisis presented by antibiotic-resistant bacterial infections. Simultaneously, we are looking to further enhance the competitiveness and global status of the Korean bio-industry. MicrobiotiX will continue to grow as a Korean biotech company that leads the development of innovative anti-infective drugs.” The content above comes from the network.if any infringement, please contact us to modify.